Cargando…
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
We performed this dose-finding study with a fixed dose of cisplatin and increasing doses of paclitaxel given every 2 weeks to determine the maximum tolerable dose of this schedule. Sixty-four patients with advanced oesophageal cancer were treated with a cisplatin dose of 60 mg m(−2) and increasing d...
Autores principales: | Gaast, A van der, Kok, T C, Kerkhofs, L, Siersema, P D, Tilanus, H W, Splinter, T A W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363040/ https://www.ncbi.nlm.nih.gov/pubmed/10362115 http://dx.doi.org/10.1038/sj.bjc.6690462 |
Ejemplares similares
-
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002) -
Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.
por: Kok, T. C., et al.
Publicado: (1996) -
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
por: Polee, M B, et al.
Publicado: (2003) -
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
por: van Meerten, E, et al.
Publicado: (2006) -
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)